Table 2 |.
Serum biochemistries at termination (CKD study)
| Group | n | BUN (mg/dL) | Serum Cr (mg/dL) | Serum Ca (mg/dL) | Serum P (mg/dL) | Serum ALP (U/L) | Serum PTH (pg/mL) | Serum OPG (pg/mL) | Serum FGF23 (pg/mL) |
|---|---|---|---|---|---|---|---|---|---|
| WT-CKD/NP | 6 | 37 ± 3 | 0.28 ± 0.02 | 11.0 ± 0.2 | 7.0 ± 0.3 | 164 ± 7 | 473 ± 71 | 4467 ± 365 | 1539 ± 226 |
| PiT-2 HET-CKD/NP | 5 | 36 ± 2 | 0.30 ± 0.01 | 10.1 ± 0.2 | 8.6 ± 0.3 | 168 ± 10 | 660 ± 20 | 4743 ± 509 | 2670 ± 387 |
| WT-CKD/HP | 8 | 32 ± 2 | 0.29 ± 0.05 | 9.9 ± 0.3 | 10.0 ± 0.7 a | 146 ± 8 | 1490 ± 144 a | 5707 ± 379 | 6507 ± 1037 a |
| PiT-2 HET-CKD/HP | 10 | 43 ± 5 | 0.27 ± 0.04 | 9.1 ±0.3 | 10.4 ± 0.9 b | 165 ± 8 | 1462 ± 231 b | 4193 ± 360 c | 5618 ± 1307 b |
Data are expressed as mean ± SEM and compared by one-way ANOVA followed by Tukey-Kramer test. A P-value less than 0.05 was considered statistically significant.
a
P<0.05 versus WT-CKD/NP
b
P<0.05 versus PiT-2 HET-CKD/NP
c
P<0.05 versus WT-CKD/HP.
ALP, alkaline phosphatase; BUN, blood urea nitrogen; Ca, calcium; CKD, chronic kidney disease; Cr, creatinine; FGF23, fibroblast growth factor 23; HP, high (1.5%) P; NP, normal (0.5%) P; OPG, osteoprotegerin; P, phosphate; PiT-2 HET, PiT-2 heterozygous knockout; PTH, parathyroid hormone; WT, wild-type.